HMNC highly contributes to the improvement of treatment strategies against depression and anxiety disorders by pushing the development of new chemical compounds, gene tests and biomarkers.
The objective of HMNC is to enable a more precise characterization of patients suffering from depression or anxiety disorders by means of gene tests and biomarkers, leading to an improved identification of those patients who will benefit from specific personalized treatments.
Such compounds already exist but have not been marketed due to a lack of suitable gene tests and biomarkers. HMNC is in possession of such laboratory markers and is conducting clinical studies to prove that personalized treatment of depression based on laboratory markers is a progressive innovation with high market potential.
HMNC invests in research projects and patents in order to develop profitable therapy concepts in cooperation with investors.